Acesion Pharma Launches Phase 2 Trial for Innovative AF Treatment
AP31969 is a pioneering oral SK ion channel inhibitor tailored for controlling rhythm in atrial fibrillation. This treatment has recently succeeded in Phase 1 with healthy volunteers.
The Phase 2 trial will evaluate AP31969's effectiveness against atrial fibrillation burden and will analyze its safety profile through continuous cardiac monitoring.
Acesion Pharma, a groundbreaking biotech firm focused on advancing treatments for atrial fibrillation (AF), has begun the enrollment of patients for its Phase 2 clinical trial. This randomized, double-blind, placebo-controlled trial is designed to assess the efficacy and safety of AP31969 in patients diagnosed with AF. The trial aims to enroll around 200 participants, spanning across eight European countries, with the goal of completing the study by early 2027.
The chief efficacy measure in this trial is the burden of AF, which is defined as the proportion of time a participant experiences this condition. Alongside this, a pivotal safety measure will monitor any occurrence of proarrhythmia in the heart's ventricles. Notably, ventricular proarrhythmia is a significant safety concern with the currently available antiarrhythmic medications. To ensure thorough evaluations of these endpoints, patients in the trial will be equipped with an implantable loop recorder, facilitating continuous monitoring of their cardiac rhythm.
Interestingly, Acesion recently completed a successful Phase 1 clinical trial of AP31969, which involved 92 healthy volunteers. This initial trial incorporated both a single ascending dose (SAD) and a multiple ascending dose (MAD) approach to evaluate the compound's safety, pharmacokinetics, and impact on the QT interval (QTc). It was found that AP31969 maintains a favorable safety profile and pharmacokinetics that are suitable for chronic oral use. Importantly, the study also showed that potentially harmful effects on QTc were negligible, reinforcing the compound's safety in relation to the proarrhythmia risks that are typical of many current antiarrhythmic drugs.
Anders Gaarsdal Holst, MD, PhD, Chief Executive Officer of Acesion, expressed: "The advancement of our oral lead compound AP31969 into a Phase 2 trial represents a crucial milestone for Acesion. By utilizing implantable loop recorders during the trial, we can accurately measure AF burden efficacy and better understand the risk of proarrhythmia. Gaining insight into both efficacy and safety within this therapeutic area is quite rare for a Phase 2 cardiovascular trial. If we achieve favorable results, this will significantly de-risk the pathway to Phase 3 development and expedite AP31969's journey to becoming the preferred treatment for the growing number of patients battling AF."
Acesion Pharma is dedicated to developing groundbreaking therapies for AF, aiming to enhance the quality of life for millions globally. With the rise in AF diagnoses, it is projected that the combined patient population in both the US and EU could reach 25 million by 2030. Acesion has taken the lead in developing SK ion-channel inhibitors, positioning AP31969 as a prospective first-line treatment option for AF, effectively addressing the major safety issues linked to proarrhythmia that existing therapies face.
About Acesion Pharma
Acesion builds on two decades of expertise in developing small-molecule SK inhibitors and is leveraging this novel mechanism for controlling rhythm in atrial fibrillation.
In preclinical studies, the inhibition of SK channels has exhibited significant antiarrhythmic influences in the atria without adverse effects on the ventricles, which are the heart's primary chambers and often the source of safety concerns with existing medications. Moreover, strong genetic validation of the SK channel suggests a robust association with AF, confirmed by findings from human genome-wide association research.
Acesion is the sole company effectively progressing the development of SK inhibitors into clinical trials, having demonstrated notable efficacy with its earlier SK channel inhibitor, AP30663, in pharmacological AF cardioversion. The oral formulation, AP31969, currently in Phase 2 trials, is specifically designed to enhance AF management without compromising patient safety. This therapy is anticipated to emerge as a first-choice chronic treatment for AF by mitigating the serious risks of proarrhythmia linked to existing treatments.
Acesion enjoys support from various investors, including Novo Holdings, Canaan, Alpha Wave Ventures, Global BioAccess Fund, Wellcome Trust, Broadview Ventures, and FC Capital.
About Atrial Fibrillation (AF)
Atrial fibrillation is recognized as the most prevalent cardiac arrhythmia. The growing incidence of this condition is anticipated to see the combined patient population in the US and EU reaching 25 million by 2030. The probability of developing AF over a lifetime exceeds one in three. Characterized by irregular electrical activity within the heart's upper chambers (the atria), AF can lead to chaotic heart rhythms and elevated heart rates. This condition is associated with reduced quality of life and significantly increases the risk of hospitalization and strokes, with recent research indicating a link to cognitive impairments and dementia.
Current medication therapies for rhythm control in AF carry a risk of severe cardiac or other adverse effects, underscoring the urgent need for safer solutions. Unfortunately, innovation in this space has stagnated, with no new chronic AF medications approved for upwards of two decades.
One pivotal clinical trial published in a premier medical journal encompassing rhythm control has evidenced that this approach enhances survival and promotes favorable long-term outcomes in AF patients, further emphasizing the necessity for safer treatment pathways.
Frequently Asked Questions
What is AP31969?
AP31969 is an oral SK ion channel inhibitor designed to control rhythm in patients with atrial fibrillation.
What is the main goal of the Phase 2 trial?
The primary goal is to assess the efficacy of AP31969 on AF burden and its safety profile through continuous cardiac monitoring.
How many patients are expected to enroll in the trial?
The trial aims to enroll approximately 200 patients across multiple European countries.
What makes this trial significant?
This trial is unique as it incorporates implantable loop recorders for accurate measurement of AF burdens and safety monitoring.
How does AP31969 differ from existing treatments?
AP31969 is designed to improve efficacy while minimizing safety risks associated with proarrhythmia seen in current therapies.
